Market Cap
$592.7M
CTMX
CytomX Therapeutics, Inc.
$2.58 ▼ -2.09%
Prev close $2.63Market cap$592.7M
ConsensusStrong Buy
12-mo target$12.25 (+375.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)28 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CTMX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (93%)
Inst. Holders
50 funds
Inst. Value
$551.5M
Inst. Activity
28 buys / 13 sells
Insider Activity
$0.00 buy / $1.2M sell
Insider Net $
-$1.2M
Social Sentiment
67° Warm
SEC Reports
1
Press Releases
4
Price chart 30d -30.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: CTMX — 61.9% short (0.7M / 1.2M)
Short: 711,749 | Exempt: 113 | TRF Vol: 1,150,651 | Short Ratio: 61.9% | Off-exchange volume (dark p
Aug 3, 2026 Insider
Carvajal Alejandra was granted 450,000 shares
Chief Legal Officer
Aug 3, 2026 Insider
Carvajal Alejandra was granted 100,000 shares
Chief Legal Officer
Jul 24, 2026 Insider
Fuchs Charles S. was granted 118,000 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
17,559,822 shares ($65.8M)
Jun 30, 2026 Inst.
Jun 23, 2026 SEC BANK OF AMERICA CORP — ADD
15,082,617 shares ($56.6M)
CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockholders approved a char
8-K — Impact 3/10
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30
Impact 6/10
Analyst ratings buy % +8.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
93% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 13, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 10, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% |
Price targets
Where 8 covering analysts think CTMX trades over the next 12 months.
$12.25 +375.7% upside Strong Buy
Current$2.58 Low$6.00 Median$12.00 High$16.00 8 analysts
$6.00$16.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 3.0/10.Plus 4 press releases.
NEUTRAL8-K3/10
CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockhol
Jun 23, 2026
NEUTRAL6/10
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,
Mar 18, 2026
BEARISH7/10
CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded war
Mar 16, 2026
MIXED6/10
CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue declin
Mar 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: CTMX — 61.9% short (0.7M / 1.2M)
Short: 711,749 | Exempt: 113 | TRF Vol: 1,150,651 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: CTMX — 59.2% short (1.1M / 1.9M)
Short: 1,120,230 | Exempt: 113 | TRF Vol: 1,890,941 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: CTMX — 70.3% short (0.7M / 1.0M)
Short: 687,130 | Exempt: 0 | TRF Vol: 977,950 | Short Ratio: 70.3% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: CTMX — 66.8% short (0.9M / 1.3M)
Short: 881,329 | Exempt: 6,522 | TRF Vol: 1,319,775 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: CTMX — 59.7% short (0.7M / 1.2M)
Short: 737,327 | Exempt: 0 | TRF Vol: 1,234,310 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.07 | $-0.11–$0.03 | 21.4% | +0.0% | 4↑ 1↓ | $0.0B | 7 |
| Next Q | $-0.10 | $-0.13–$-0.06 | 53.2% | +0.0% | 3↑ 3↓ | $0.0B | 7 |
| Current FY | $-0.39 | $-0.52–$-0.28 | -160.1% | +0.0% | 4↑ 1↓ | $0.0B | 7 |
| Next FY | $-0.47 | $-0.67–$-0.16 | -21.3% | +0.0% | 4↑ 3↓ | $0.0B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.071 | — |
| 7d ago | $-0.071 | — |
| 30d ago | $-0.071 | — |
| 60d ago | $-0.105 | +0.034 |
| 90d ago | $-0.105 | +0.034 |
Institutional ownership
Which big funds own CTMX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $551.5M total value (147,044,973 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, BANK. Net buying activity: 28 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 32,714,937 | $122.7M | 22.2% | ADD +29.4% |
| BlackRock, Inc. | 17,559,822 | $65.8M | 11.9% | DOUBLED +235.9% |
| BANK OF AMERICA CORP /DE/ | 15,082,617 | $56.6M | 10.3% | ADD +47.8% |
| STATE STREET CORP | 11,747,236 | $44.1M | 8.0% | DOUBLED +107.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,525,457 | $32.0M | 5.8% | — |
| Point72 Asset Management, L.P. | 7,811,033 | $29.3M | 5.3% | ADD +51.8% |
| WELLINGTON MANAGEMENT GROUP LLP | 5,168,961 | $19.4M | 3.5% | ADD +44.3% |
| BAKER BROS. ADVISORS LP | 4,975,826 | $18.7M | 3.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,678,716 | $17.5M | 3.2% | DOUBLED +126.4% |
| TWO SIGMA INVESTMENTS, LP | 4,132,643 | $15.5M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 5,228,280 | 17,559,822 | +235.9% | $65.8M |
| BANK OF AMERICA CORP /DE/ | ADD | 10,202,785 | 15,082,617 | +47.8% | $56.6M |
| STATE STREET CORP | DOUBLED | 5,663,408 | 11,747,236 | +107.4% | $44.1M |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 3,582,985 | 5,168,961 | +44.3% | $19.4M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 2,066,612 | 4,678,716 | +126.4% | $17.5M |
| CITADEL ADVISORS LLC | TRIM | 5,406,193 | 3,110,509 | -42.5% | $11.7M |
| MARSHALL WACE, LLP | TRIM | 4,138,176 | 3,024,351 | -26.9% | $11.3M |
| GOLDMAN SACHS GROUP INC | ADD | 1,459,839 | 2,003,652 | +37.3% | $7.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 794,755 | 1,751,167 | +120.3% | $6.6M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 3,660,190 | 1,685,830 | -53.9% | $6.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 26 transactions. Net -$1.2M — $0.00 bought, $1.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Carvajal Alejandra | Chief Legal Officer | AWARD | 450,000 | — | — |
| Aug 3, 2026 | Carvajal Alejandra | Chief Legal Officer | AWARD | 100,000 | — | — |
| Jul 24, 2026 | Fuchs Charles S. | Director | AWARD | 118,000 | — | — |
| Jun 17, 2026 | Ashworth Alan | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Mohindru Mani | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Jones Elaine V | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Su Zhen | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Young Matthew P. | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Gilbert Halley E | Director | AWARD | 59,000 | — | — |
| Jun 17, 2026 | Meyers James R | Director | AWARD | 59,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CTMX.
Shares short
38,639,220
Settlement Sep 15, 2026
Change vs prior
+15.3%
Semi-monthly cycle
Days to cover
9.3
At avg daily volume
Of shares outstanding
≈17.7%
Estimate — not % of float
All CTMX filing & press-release reports (5)
- 8-K reportJun 23, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 4, 2026